title: Reply to s. Bonovas et Al, s. Clement et Al, and j.L. Lund et Al.
authors.affiliation: National Taiwan University College of Public Health, Taipei; Taichung Veterans General Hospital; and Chung Shan Medical University School of Medicine, Taichung, Taiwan.
authors.forename: Yu-Tse
authors.initials: YT
authors.lastname: Tsan
authors.forename: Chang-Sing
authors.initials: CS
authors.lastname: Lee
authors.forename: Wen-Chao
authors.initials: WC
authors.lastname: Ho
authors.forename: Meng-Hung
authors.initials: MH
authors.lastname: Lin
authors.forename: Jung-Der
authors.initials: JD
authors.lastname: Wang
authors.forename: Pau-Chung
authors.initials: PC
authors.lastname: Chen
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000209:etiology*; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000209:etiology*; D008297:Male
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors